Department of Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Robert D. and Patricia E. Kern Mayo Clinic Center for the Science of Health Care Delivery, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
BMC Fam Pract. 2019 Jan 22;20(1):17. doi: 10.1186/s12875-019-0906-y.
Healthcare providers play a critical role in facilitating patient access to medical cannabis. However, previous surveys suggest only a minority of providers believe that medical cannabis confers benefits to patients. Significant new knowledge about the potential benefits and harms of medical cannabis has recently emerged. Understanding current attitudes and beliefs of providers may provide insight into the ongoing challenges they face as states expand access to medical cannabis.
We conducted an electronic survey of primary care providers in a large Minnesota-based healthcare system between January 23 and February 5, 2018. We obtained information about provider characteristics, attitudes and beliefs about medical cannabis, provider comfort level in answering patient questions about medical cannabis, and whether providers were interested in receiving additional education.
Sixty-two providers completed the survey (response rate 31%; 62/199). Seventy-six percent of respondents were physicians and the average age was 46.3 years. A majority of providers believed ("strongly agree" or "somewhat agree") that medical cannabis was a legitimate medical therapy (58.1%) and 38.7% believed that providers should be offering to patients for managing medical conditions. A majority (> 50%) of providers believed that medical cannabis was helpful for treating the qualifying medical conditions of cancer, terminal illness, and intractable pain. A majority of providers did not know if medical cannabis was effective for managing nearly one-half of the other state designated qualifying medical conditions. Few believed that medical cannabis improved quality of life domains. Over one-third of providers believed that medical cannabis interacted with medical therapies. One-half of providers were not ready to or did not want to answer patient questions about medical cannabis, and the majority of providers wanted to learn more about it.
Healthcare providers generally believe that medical cannabis is a legitimate medical therapy. Provider knowledge gaps about the effectiveness of medical cannabis for state designated qualifying conditions need to be addressed, and accurate information about the potential for drug interactions needs to be disseminated to address provider concerns. Clinical trial data about how medical cannabis improves patient quality of life domains is desperately needed as this information can impact clinical decision-making.
医疗保健提供者在促进患者获得医用大麻方面发挥着关键作用。然而,之前的调查表明,只有少数提供者认为医用大麻对患者有益。最近出现了大量关于医用大麻潜在益处和危害的新知识。了解提供者当前的态度和信念,可以深入了解他们在各州扩大医用大麻获取途径时所面临的持续挑战。
我们于 2018 年 1 月 23 日至 2 月 5 日期间,对明尼苏达州一家大型医疗保健系统中的初级保健提供者进行了电子调查。我们获得了提供者特征、对医用大麻的态度和信念、提供者在回答患者关于医用大麻问题时的舒适度以及提供者是否有兴趣接受额外教育等方面的信息。
62 名提供者完成了调查(回应率 31%;62/199)。76%的受访者为医生,平均年龄为 46.3 岁。大多数提供者认为(“强烈同意”或“有些同意”)医用大麻是一种合法的医疗疗法(58.1%),38.7%的人认为提供者应为患者提供医用大麻以治疗医疗状况。大多数提供者认为医用大麻对治疗合格医疗条件下的癌症、终末期疾病和难治性疼痛有帮助(>50%)。大多数提供者不知道医用大麻对管理近一半其他州指定的合格医疗条件是否有效。很少有提供者认为医用大麻改善了生活质量领域。超过三分之一的提供者认为医用大麻与医疗疗法相互作用。有一半的提供者还没有准备好或不想回答患者关于医用大麻的问题,大多数提供者希望了解更多相关信息。
医疗保健提供者普遍认为医用大麻是一种合法的医疗疗法。需要解决提供者在医用大麻对州指定合格条件的有效性方面的知识差距,并传播关于潜在药物相互作用的准确信息,以解决提供者的担忧。迫切需要关于医用大麻如何改善患者生活质量领域的临床试验数据,因为这些信息会影响临床决策。